ValiRx plc (VAL) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.179x

Based on the latest financial reports, ValiRx plc (VAL) has a cash flow conversion efficiency ratio of -0.179x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-700.73K ≈ $-941.02K USD) by net assets (£3.92 Million ≈ $5.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

ValiRx plc - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how ValiRx plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does ValiRx plc carry for a breakdown of total debt and financial obligations.

ValiRx plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ValiRx plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
ICZOOM Group Inc. Class A Ordinary Shares NASDAQ:IZM	0.083x
Public Policy Holding Company Inc LSE:PPHC	0.118x
Glacier Lake Resources Inc V:GLI	0.010x
Society Pass Inc NASDAQ:SOPA	-1.219x
Zonetail Inc V:ZONE	0.041x
Commander Resources Ltd V:CMD	-0.123x
Nobel29 Resources Corp V:NBLC	0.055x
CME Group Bhd KLSE:7018	0.059x

Annual Cash Flow Conversion Efficiency for ValiRx plc (2001–2024)

The table below shows the annual cash flow conversion efficiency of ValiRx plc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see ValiRx plc (VAL) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	£3.92 Million ≈ $5.26 Million	£-1.58 Million ≈ $-2.13 Million	-0.405x	+33.68%
2023-12-31	£2.90 Million ≈ $3.90 Million	£-1.77 Million ≈ $-2.38 Million	-0.610x	-36.39%
2022-12-31	£3.83 Million ≈ $5.14 Million	£-1.71 Million ≈ $-2.30 Million	-0.447x	-21.21%
2021-12-31	£3.41 Million ≈ $4.59 Million	£-1.26 Million ≈ $-1.69 Million	-0.369x	+8.12%
2020-12-31	£4.76 Million ≈ $6.39 Million	£-1.91 Million ≈ $-2.57 Million	-0.402x	+33.42%
2019-12-31	£2.22 Million ≈ $2.99 Million	£-1.34 Million ≈ $-1.80 Million	-0.604x	+45.45%
2018-12-31	£3.03 Million ≈ $4.07 Million	£-3.35 Million ≈ $-4.50 Million	-1.106x	-48.34%
2017-12-31	£3.15 Million ≈ $4.23 Million	£-2.35 Million ≈ $-3.16 Million	-0.746x	+58.08%
2016-12-31	£2.37 Million ≈ $3.18 Million	£-4.22 Million ≈ $-5.66 Million	-1.779x	-211.40%
2015-12-31	£4.53 Million ≈ $6.09 Million	£-2.59 Million ≈ $-3.48 Million	-0.571x	+47.02%
2014-12-31	£2.79 Million ≈ $3.74 Million	£-3.01 Million ≈ $-4.04 Million	-1.079x	-68.52%
2013-12-31	£3.23 Million ≈ $4.34 Million	£-2.07 Million ≈ $-2.78 Million	-0.640x	-62.79%
2012-12-31	£5.04 Million ≈ $6.76 Million	£-1.98 Million ≈ $-2.66 Million	-0.393x	-19.06%
2011-12-31	£4.42 Million ≈ $5.94 Million	£-1.46 Million ≈ $-1.96 Million	-0.330x	-32.96%
2010-12-31	£2.00 Million ≈ $2.68 Million	£-496.00K ≈ $-666.08K	-0.248x	+75.67%
2009-12-31	£907.00K ≈ $1.22 Million	£-926.00K ≈ $-1.24 Million	-1.021x	-76.42%
2008-12-31	£1.37 Million ≈ $1.84 Million	£-794.00K ≈ $-1.07 Million	-0.579x	-15.19%
2007-12-31	£1.67 Million ≈ $2.24 Million	£-839.00K ≈ $-1.13 Million	-0.502x	-2848.55%
2006-12-31	£2.69 Million ≈ $3.61 Million	£-45.77K ≈ $-61.46K	-0.017x	+95.01%
2006-03-31	£161.00K ≈ $216.21K	£-55.00K ≈ $-73.86K	-0.342x	-210.08%
2005-12-31	£-203.00K ≈ $-272.61K	£-63.00K ≈ $-84.60K	0.310x	-90.48%
2004-12-31	£-69.00K ≈ $-92.66K	£-225.00K ≈ $-302.15K	3.261x	+195.24%
2003-12-31	£67.00K ≈ $89.97K	£74.00K ≈ $99.38K	1.104x	+108.81%
2002-12-31	£-141.00K ≈ $-189.35K	£1.77 Million ≈ $2.37 Million	-12.539x	-759.53%
2001-12-31	£1.00 Million ≈ $1.35 Million	£1.91 Million ≈ $2.56 Million	1.901x	--

About ValiRx plc

LSE:VAL UK Biotechnology

Market Cap

$279.27 Million

£207.96 Million GBP

Market Cap Rank

#29179 Global

#584 in UK

Share Price

£0.28

Change (1 day)

+0.00%

52-Week Range

£0.24 - £0.75

All Time High

£3312.50